World Congress of Mountain Jews

Praxis Precision Medicines Provides Corporate Update and Reports First Quarter 2023 Financial Results

Retrieved on: 
Thursday, May 11, 2023

BOSTON, May 11, 2023 (GLOBE NEWSWIRE) -- Praxis Precision Medicines, Inc. (NASDAQ: PRAX), a clinical-stage biopharmaceutical company translating genetic insights into the development of therapies for central nervous system (CNS) disorders characterized by neuronal excitation-inhibition imbalance, today provided a corporate update and reported financial results for the first quarter 2023.

Key Points: 
  • Cash and investments of $85.8 million as of March 31, 2023 supports runway into 2Q24
    BOSTON, May 11, 2023 (GLOBE NEWSWIRE) -- Praxis Precision Medicines , Inc. (NASDAQ: PRAX), a clinical-stage biopharmaceutical company translating genetic insights into the development of therapies for central nervous system (CNS) disorders characterized by neuronal excitation-inhibition imbalance, today provided a corporate update and reported financial results for the first quarter 2023.
  • The Company intends to initiate a PRAX-628 Phase 2 study for the treatment of focal epilepsy in the fourth quarter of 2023.
  • Praxis expects topline results from the PRAX-562 Phase 2 EMBOLD study for the treatment of pediatric patients with developmental and epileptic encephalopathies (DEEs) in the fourth quarter of 2023.
  • In April 2023, Praxis presented the following posters at the 75th Annual American Academy of Neurology (AAN) meeting:

South Rampart Pharma Announces Late-Breaking Presentation at IASP 2022 World Congress on Pain

Retrieved on: 
Thursday, August 25, 2022

NEW ORLEANS, Aug. 25, 2022 /PRNewswire/ -- South Rampart Pharma ("South Rampart" or the "Company"), a clinical-stage life science company advancing innovative medications for the treatment of pain and fever, today announced that the Company will present a late-breaking abstract at the International Association for the Study of Pain (IASP) 2022World Congress on Pain, which will take place on September 20-23, 2022, in Toronto, Canada.

Key Points: 
  • NEW ORLEANS, Aug. 25, 2022 /PRNewswire/ -- South Rampart Pharma ("South Rampart" or the "Company"), a clinical-stage life science company advancing innovative medications for the treatment of pain and fever, today announced that the Company will present a late-breaking abstract at the International Association for the Study of Pain (IASP) 2022World Congress on Pain, which will take place on September 20-23, 2022, in Toronto, Canada.
  • South Rampart's CEO and Co-founder, Hernan Bazan, MD, FACS, will deliver the presentation.
  • The World Congress on Pain is the largest global gathering of pain professionals.
  • South Rampart Pharma is a clinical-stage life science company dedicated to advancing the safe treatment of pain by developing new small molecule solutions that can overcome many risks associated with current pain medicines.